GLOW vs KLOW
KLOW is the GLOW blend with 10 mg of KPV added. GLOW is one 70 mg vial of GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg; KLOW is one 80 mg vial of the same three plus KPV 10 mg. No published study has tested either blend, so the evidence for both is single-compound work.
Side by side
| GLOW blend | KLOW | |
|---|---|---|
| Class | Three-peptide research blend | Four-peptide research blend |
| What's in the vial | GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg = 70 mg (5 : 1 : 1 by mass) | GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg = 80 mg (5 : 1 : 1 : 1 by mass) |
| What's studied (by component) | GHK-Cu: skin, fibroblasts, wounds. BPC-157: rat injury models. TB-500: thymosin beta-4 in mouse heart, airway and tissue models | The same three, plus KPV: mouse and rat colitis models and inflammatory signalling in cells |
| Strength of the evidence | No study of the blend. Component work is mostly mouse, rat and cell; the human records are a 13-patient topical GHK-Cu trial and a 12-patient uncontrolled BPC-157 pilot | No study of the blend. Component work is mostly mouse, rat and cell; KPV has no human studies in our records |
| Forms sold here | Lyophilised powder, single blend vial | Lyophilised powder, single blend vial |
| Sizes sold here | 70 mg vial | 80 mg vial |
| Storage | −20 °C, dry and dark; 2–8 °C once mixed, use within 28 days | −20 °C, dry and dark; 2–8 °C once mixed, use within 28 days |
| Cited studies on our pages | 8 | 8 |
Key differences
Contents: the only difference in the vial is KPV. KLOW adds 10 mg of KPV to the same GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg found in GLOW, taking the total from 70 mg to 80 mg.
What KPV adds to the research picture: KPV is the Lys-Pro-Val end of alpha-MSH, studied mainly in mouse and rat colitis for its effect on NF-kB and MAP kinase inflammatory signalling. GLOW's three components are studied mainly in skin, wound and tissue injury models.
Evidence: neither blend has been tested as a mixture. Each blend page groups its eight studies by component, and KLOW's set includes two KPV colitis studies in place of some of the GLOW component records.
FAQ
What is the difference between GLOW and KLOW?
KLOW is GLOW plus KPV. GLOW holds GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg in one 70 mg vial. KLOW holds the same three plus KPV 10 mg in one 80 mg vial.
What is KPV?
KPV is a tripeptide of lysine, proline and valine, the C-terminal residues 11 to 13 of alpha-melanocyte-stimulating hormone. In cell studies it inhibited NF-kB and MAP kinase inflammatory signalling, and most of its animal work is in mouse and rat colitis models. There are no human studies of KPV in our records.
Has anyone studied the GLOW or KLOW blend?
No. No published study has tested GHK-Cu, BPC-157 and TB-500 together, with or without KPV. The closest record is a knee pain chart review in which 4 of 16 people had BPC-157 with thymosin beta-4, with no control group.
Are GLOW and KLOW legal in Australia?
None of the components is registered on the ARTG as a medicine, and there is no TGA-approved product containing either blend. BPC-157 and TB-500 also have Schedule 4 entries in the Poisons Standard. Tasman supplies both blends for laboratory research only, not for human use.